Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 3/1998

01-05-1998

Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma

Authors: Kenji Jin-no, Masahito Tanimizu, Ichinosuke Hyodo, Yoshiyuki Nishikawa, Yasushi Hosokawa, Toshihiko Doi, Hisashi Endo, Tetsuji Yamashita, Yoshio Okada

Published in: Journal of Gastroenterology | Issue 3/1998

Login to get access
Metadata
Title
Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma
Authors
Kenji Jin-no
Masahito Tanimizu
Ichinosuke Hyodo
Yoshiyuki Nishikawa
Yasushi Hosokawa
Toshihiko Doi
Hisashi Endo
Tetsuji Yamashita
Yoshio Okada
Publication date
01-05-1998
Publisher
Springer-Verlag
Published in
Journal of Gastroenterology / Issue 3/1998
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s005350050099

Other articles of this Issue 3/1998

Journal of Gastroenterology 3/1998 Go to the issue

Letter to the editor

GB virus C/hepatitis G virus infection in autoimmune liver diseases

Review

Ulcerative colitis and Crohn's disease—susceptibility genes and clinical patterns

OriginalPaper

Altered hepatic hemodynamics and improved liver function following intrahepatic vascular infusion of prostaglandin E1

Case report

Fulminant hepatitis complicated by small intestine infection and massive hemorrhage

OriginalPaper

Effects of transjugular intrahepatic portosystemic shunt (TIPS) on esophageal motor function and gastroesophageal reflux

OriginalPaper

Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits